8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 9, 2005)

Filed November 9, 2005For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on November 9, 2005, to announce its financial results for the third quarter ended September 30, 2005. While the 8-K itself is a brief procedural filing, it incorporates by reference a press release that contains the substantive financial and operational details. Investors should refer to the furnished press release (Exhibit 99.1) for comprehensive information regarding the company's performance during the period. The filing indicates that the company is providing updates on its operational and financial standing. As a clinical-stage biopharmaceutical company, the focus for investors is typically on pipeline progress, research and development expenditures, and any significant corporate developments. Investors are advised to examine the detailed financial results and management's commentary provided in the accompanying press release to understand the company's current financial condition and its strategic direction.

Key Highlights

  • 1Announcement of Q3 2005 financial results by Alnylam Pharmaceuticals, Inc.
  • 2Filing date: November 9, 2005.
  • 3The 8-K serves as a cover for a press release containing detailed financial results.
  • 4Press release (Exhibit 99.1) is furnished, not filed, and contains the core operational and financial information.
  • 5Information pertains to the quarter ended September 30, 2005.
  • 6The company is identified as Alnylam Pharmaceuticals, Inc., incorporated in Delaware.
  • 7Key executive signing the report is John M. Maraganore, President and Chief Executive Officer.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce Alnylam Pharmaceuticals, Inc.'s financial results for the third quarter ended September 30, 2005. It officially incorporates a press release containing these details.

The detailed financial and operational information is contained within the press release dated November 9, 2005, which is furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to this exhibit for comprehensive data.

These financial results cover the third quarter ended September 30, 2005.

No, the information contained in this 8-K, including the press release, is furnished rather than filed. This means it is not subject to the liabilities under Section 18 of the Exchange Act, although it can be incorporated by reference into other filings if explicitly stated.